Majority of younger patients dying of cancer use aggressive interventions in last month of life
the ONA take:
According to a recent study published in JAMA Oncology, researchers at Dana-Farber Cancer Institute/Boston Children's Cancer and Blood Disorders Center and Kaiser Permanente Southern California have found that more than two-thirds of adolescents and young adults dying as a result of cancer underwent at least one aggressive intervention during the last month of life.
For the study, researchers evaluated the use of intensive care, the emergency room, chemotherapy, and/or hospitalization in the last month of life in 633 patients aged 15 to 39 years who died of cancer between 2001 and 2010.
Results showed that young patients were more than two times as likely as patients 65 and older to receive intensive care and/or use the emergency room during the last month of life. The rate of use of chemotherapy and hospitalization was similar among both age groups. Researchers found that 22% of the adolescents and young adults used intensive care and/or the emergency room in the last month of life, 11% received chemotherapy in the last two weeks of life, and 62% were hospitalized in the last month of life.
The findings suggest that further research is warranted to determine whether younger patients dying of cancer have been adequately supported to make their end-of-life decisions.
More than two-thirds of adolescents and young adults dying as a result of cancer underwent at least one aggressive intervention during the last month of life.
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Longer Maintenance Therapy Duration May Improve Survival in Myeloma
- HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma
- MRD Assessment Improves PFS Prediction in Patients With CLL
- Cancer Patients Have Unrealistic Hopes When Entering Clinical Trials
- Ofatumumab With Fludarabine, Cyclophosphamide Approved for Relapsed CLL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|